Literature DB >> 11172518

Labor analgesia in a patient with paroxysmal nocturnal hemoglobinuria with thrombocytopenia.

R M Stocche1, L V Garcia, J G Klamt.   

Abstract

BACKGROUND AND OBJECTIVES: Paroxysmal nocturnal hemoglobinuria (PNH) is a form of acquired hemolytic anemia in which a defect of glycophosphatidylinositol anchor proteins in the cell membrane of bone marrow stem cells leads to activation of the complement system and consequent destruction of defective cells. The characteristics of this disease are an increased frequency of thrombotic events, anemia, and thrombocytopenia.
METHODS: We report a case of a pregnant patient with PNH with thrombocytopenia who delivered vaginally after receiving epidural labor analgesia. Prophylaxis of thromboembolism was performed with heparin 1 hour after the removal of the epidural catheter, and repeated at 12-hour intervals. Sensory changes or motor changes and pain were monitored every 10 minutes for 8 hours after delivery.
RESULTS: During analgesia, the patient reported complete pain relief. Delivery and the immediate postpartum period were without any untoward events.
CONCLUSIONS: Four major factors influenced the anesthetic conduct used for the present patient: (1) the risk of an acute hemolytic crisis, (2) the need to perform prophylaxis for thromboembolism, (3) the need to reduce labor stress, and (4) minimizing the risk of missing an epidural hematoma. We also present a survey of the literature about PNH and discuss the anesthetic conduct in this patient.

Entities:  

Mesh:

Year:  2001        PMID: 11172518     DOI: 10.1053/rapm.2001.19634

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  1 in total

Review 1.  Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era.

Authors:  Yasuyoshi Morita; Jun-ichi Nishimura; Takahiro Shimada; Hirokazu Tanaka; Kentaro Serizawa; Yasuhiro Taniguchi; Mitsuhiro Tsuritani; Yuzuru Kanakura; Itaru Matsumura
Journal:  Int J Hematol       Date:  2013-03-02       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.